× Close Video

Neurovation Labs is revolutionizing how to diagnose and treat psychiatric illness, starting with Post-Traumatic Stress Disorder.
Watch Video ▶

Neurovation Labs, Inc. Secures Seed Funding for Post-traumatic Stress Disorder Diagnostic

October 24, 2016

NEW YORK–(Business Wire)–Neurovation Labs, Inc., a biotechnology company developing Post-traumatic Stress Disorder (“PTSD”) diagnostics and treatments, is pleased to announce that it has successfully raised its seed funding round earlier this month. This financing was completed with the support of individual angel investors based in the United States.
Neurovation Labs intends to use the proceeds to further the development of its patent-pending PTSD diagnostic. It will commence the next set of pre-clinical studies next month, testing the efficacy of using radiological imaging technology to diagnose PTSD.

Read More

Neurovation Labs, Inc. announces novel and effective methods for diagnosing and treating PTSD

April 11, 2016

New York, NY, April 11, 2016- A new New York-based biotechnology company, Neurovation Labs, Inc., is developing an objective diagnostic for Post-traumatic Stress Disorder (PTSD) and an accompanying treatment. Early research has shown that a complete reversal of PTSD is possible.

Read More